Actimis Pharmaceuticals, Inc., is a start-up biopharmaceutical company focused on the development of small molecule therapeutics for respiratory and inflammatory disorders. Actimis was created as a spin-off from the respiratory diseases therapeutic research portfolio of Bayer Healthcare AG. The spin-off was founded by Dr. Kevin Bacon and has received venture financing from a syndicate lead by Sanderling Ventures of San Mateo, California and Mitsui & Co Venture Partners of New York. Dr. Bacon was most recently Vice President and Global Head of Respiratory diseases research at Bayer Yakuhin Ltd., Japan where the programs were initiated.

Actimis’s lead program, a small molecule antagonist against the receptor CRTH2, for once-daily dosing in asthma and atopic disease is currently in phase I clinical trials. Additionally, Actimis’s portfolio contains a late-stage pre-clinical lead series of compounds against an independent target in asthma and allergic rhinitis. These compounds have been optimized to very high standards through a series of exhaustive internal controls and an intensive biology and chemistry program. Actimis’s portfolio contains three additional novel validated targets in diseases including asthma, COPD and rheumatoid arthritis. Actimis' targets are focused upon the biology of the chemokine superfamily, small proteins released from a variety of cells under a variety of both physiological and pathological conditions.